National Pension Service Acquires New Stake in DaVita Inc. $DVA

National Pension Service bought a new position in shares of DaVita Inc. (NYSE:DVA) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 9,822 shares of the company’s stock, valued at approximately $1,305,000.

A number of other hedge funds have also modified their holdings of the business. KBC Group NV boosted its position in DaVita by 38.7% during the second quarter. KBC Group NV now owns 374,749 shares of the company’s stock worth $53,383,000 after acquiring an additional 104,554 shares during the last quarter. Nordea Investment Management AB lifted its stake in DaVita by 1.8% in the 3rd quarter. Nordea Investment Management AB now owns 286,585 shares of the company’s stock worth $37,864,000 after purchasing an additional 5,193 shares in the last quarter. Man Group plc boosted its holdings in shares of DaVita by 1,608.6% during the 2nd quarter. Man Group plc now owns 285,809 shares of the company’s stock worth $40,713,000 after purchasing an additional 269,081 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its position in shares of DaVita by 132.1% in the second quarter. Arrowstreet Capital Limited Partnership now owns 264,084 shares of the company’s stock valued at $37,619,000 after purchasing an additional 150,318 shares in the last quarter. Finally, Worldquant Millennium Advisors LLC increased its holdings in shares of DaVita by 49.1% in the second quarter. Worldquant Millennium Advisors LLC now owns 257,845 shares of the company’s stock valued at $36,730,000 after purchasing an additional 84,859 shares during the last quarter. 90.12% of the stock is currently owned by institutional investors and hedge funds.

Key DaVita News

Here are the key news stories impacting DaVita this week:

• Positive Sentiment: Q4 beat — DaVita reported Q4 revenue of ~$3.62B and EPS above estimates, with margins expanding and full‑year adjusted EPS guidance raised materially above consensus, supporting a more bullish near‑term outlook. DaVita Stock Up Following Q4 Earnings & Revenue Beat, Margins Expand
• Positive Sentiment: Raised guidance — Management set FY‑2026 EPS guidance of $13.60–$15.00, above the Street, citing steady dialysis demand; that forward guidance was a key catalyst for the stock’s rally. DaVita forecasts 2026 profit above estimates on steady dialysis service demand
• Positive Sentiment: After‑hours flow and market reaction — Major outlets reported strong after‑hours buying and a sizable volume spike as investors repositioned around the beats and higher guidance. Stocks making the biggest moves after hours: Palantir, NXP Semiconductors, DaVita and more
• Neutral Sentiment: Management commentary & call — The company’s press release and earnings call described execution vs targets and patient demand trends; read the transcript/press release for management’s assumptions driving the guidance. DaVita Inc. 4th Quarter 2025 Results
• Neutral Sentiment: Analyst context — Recent price targets cluster near the low‑to‑mid $100s–$140s range (median ~$140), so the new guidance will force analysts to re‑rate estimates and targets in coming days. DaVita Inc. Releases Q4 2025 Earnings
• Negative Sentiment: Volatility & risk factors — Market commentary warns that reimbursement, regulatory changes and execution risks could keep the stock volatile despite the beat; investors should expect swings. DaVita: Some Success Is Possible, But Volatility Is Still Heavy
• Negative Sentiment: Some financials to watch — While EPS and revenue improved, third‑party summaries show cash & cash equivalents declined and liabilities rose year‑over‑year; monitor margin sustainability and cash/leveraging metrics. DaVita Inc. Releases Q4 2025 Earnings (financial highlights)

DaVita Price Performance

Shares of DVA opened at $134.55 on Wednesday. The firm has a 50-day simple moving average of $113.69 and a two-hundred day simple moving average of $124.82. The stock has a market cap of $9.50 billion, a PE ratio of 13.58, a P/E/G ratio of 0.68 and a beta of 0.99. DaVita Inc. has a 1-year low of $101.00 and a 1-year high of $178.47.

DaVita (NYSE:DVA) last posted its quarterly earnings data on Monday, February 2nd. The company reported $3.40 earnings per share for the quarter, topping analysts’ consensus estimates of $3.24 by $0.16. DaVita had a net margin of 5.47% and a negative return on equity of 586.45%. The firm had revenue of $3.62 billion during the quarter, compared to analysts’ expectations of $3.51 billion. During the same quarter last year, the company posted $2.24 EPS. The firm’s quarterly revenue was up 9.9% on a year-over-year basis. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. As a group, sell-side analysts expect that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. UBS Group reissued a “buy” rating on shares of DaVita in a research note on Monday, December 15th. Zacks Research upgraded DaVita from a “strong sell” rating to a “hold” rating in a report on Friday, November 28th. Barclays upped their price objective on shares of DaVita from $143.00 to $158.00 and gave the company an “equal weight” rating in a report on Tuesday. Truist Financial reduced their target price on shares of DaVita from $140.00 to $128.00 and set a “hold” rating on the stock in a research note on Monday, January 5th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of DaVita in a research note on Monday, December 29th. One research analyst has rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, DaVita has a consensus rating of “Hold” and an average price target of $148.60.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.